20-06-2012: Two research groups at the University of Oxford will use Population Genetics Technologies to enable studies on gene variants associated with myocardial infarction, diabetes and metabolic disease. The company has signed a collaboration agreement with the University of Oxford to provide university researchers with genetic analyses for hypothesis validation and biomarker discovery.
The first two Oxford studies to exploit this agreement are led by Mark McCarthy, Robert Turner Professor of Diabetes at the Oxford Centre for Diabetes, Endocrinology and Metabolism, and David Buck, Head of High Throughput Genomics at the Wellcome Trust Centre for Human Genetics (WTCHG).
The McCarthy group will work in partnership with Population Genetics on a population study of 74 exons from 12 genes across a population of 1000 genomic DNA samples to identify genetic associations with diabetes and metabolic disease, using the company’s GenomePooling™ technology. The studies will also inform a wider initiative led by the National Institute for Health Research (NIHR) to establish an NIHR BioResource of volunteers willing to participate in research that will map genotype to phenotype.
The Buck group, in collaboration with PROCARDIS, will use Population Genetics’ Reflex™ workflow to interrogate 3000 samples and identify genetic variants of candidate genes associated with myocardial infarction.
Medullary thymic epithelial cells (mTECs) allow the thymus to ensure that the body’s T cells are able to distinguish between potentially harmful foreign antigens and those that are produced by the body itself. A Swiss-Japanese research team suggests that mTECs do not share a common progenit ... more
In a classic case of turning an enemy into a friend, scientists have engineered a protein from flesh-eating bacteria to act as a molecular "superglue" that promises to become a disease fighter.
"We've turned the tables and put one kind of flesh-eating bacterium to good use," said Mark Howar ... more
A team led by academics from the University of Bristol reviewed 48 articles on neuroscience meta-analysis which were published in 2011 and concluded that most had an average power of around 20 per cent – a finding which means the chance of the average study discovering the effect being inve ... more
Two research groups at the University of Oxford will use Population Genetics Technologies to enable studies on gene variants associated with myocardial infarction, diabetes and metabolic disease. The company has signed a collaboration agreement with the University of Oxford to provide unive ... more
The largest ever genomic study of relapsed acute lymphoblastic leukaemia (ALL) will fund Population Genetics Technologies Ltd to identify the genetic factors in resistance to treatment by carrying out a multi-year analysis of thousands of DNA samples from relapsed ALL cases.The IntReALL con ... more
Population Genetics Technologies Ltd. has appointed Alan Schafer, PhD to the post of Chief Executive Officer. Schafer brings deep experience in research, “big pharma” management and building new businesses. He is Adjunct Professor of Innovation at Imperial College London Business School and ... more